The incidence of human papillomavirus (HPV)-related cancers is more than 35 000 cases in the United States each year. Effective HPV vaccines have been available in the United States for several years but are underused among adolescents, the target population for vaccination. Interventions to increase uptake are needed.
T he incidence of human papillomavirus (HPV)-related cancers is more than 35 000 cases in the United States each year. 1 Highly effective vaccines against HPV have been available in the United States since 2006 for girls 2,3 and 2009 for boys 4 ,5 yet are largely underused. As of 2016, only 60.4% of children aged 13 to 17 years had started the HPV vaccination series, and only approximately two-thirds of those starting the series completed it. 6 Attempts to use policy changes to increase uptake, such as mandating HPV vaccination for school entry, have been largely unsuccessful and ineffective.
7
Interventions to improve adolescent HPV vaccine uptake by other means are a national priority.
8
A key factor influencing adolescent HPV vaccination is whether and how a health care professional recommends it. 9, 10 Numerous studies [11] [12] [13] [14] [15] demonstrate that medical professionals often fail to communicate effectively about the vaccine with patients and parents. The President's Cancer Panel 8 has indicated that interventions to improve health care professionals' communication about adolescent HPV vaccination are needed.
Our group developed a 5-component health care professional communication intervention based on the precautionadoption-process model 16 to improve medical professionals' ability to effectively communicate about HPV vaccines with their adolescent patients and their parents. The present study tests our hypothesis that implementation of the intervention increases practices' adolescent HPV vaccine uptake compared with providing usual care.
Methods

Study Design
This was a 2-arm, controlled cluster randomized clinical trial that was performed between February 1, 2015, and January 31, 2016 . Because the intervention was at the practice level, cluster randomization was performed at the practice level in a 1:1 ratio. All study activities were approved by the Colorado Multiple Institutional Review Board. The study is registered with clinicaltrials.gov (identifier NCT02456077). Informed consent was waived.
Study Sites
Twenty-four practices in the Denver, Colorado, metropolitan area that were part of a 30-clinic practice-based research network were invited to participate to represent a diverse crosssection of patient and practice demographics. Inclusion criteria were being a pediatrics or family medicine practice with at least 400 active (seen within the last 2 years) adolescent patients (age range, 11-17 years). There were no exclusion criteria. Of these 24, one practice withdrew from the study before randomization owing to new competing time demands (electronic medical record implementation). Seven practices that were part of one safety-net hospital system were dropped before randomization owing to very high baseline adolescent vaccination rates (approximately 90% for series initiation 17 ). The final cohort for randomization included 16 practices (4 family medicine and 12 pediatrics) that included 188 medical professionals. Each practice participated in a series of 2 intervention development meetings over a 6-month period ( August 1, 2014 , to January 31, 2015 before officially launching the intervention.
All health care professionals who ordered vaccines for patients (ie, physicians, nurse practitioners, medical assistants, and physician assistants) in these practices could participate. Of these, 5 physicians in a single family medicine practice declined study participation owing to seeing few adolescent patients. This practice was ultimately assigned to the intervention arm, and these medical professionals' data are included in the analyses, which used an intent-to-treat protocol (Supplement 1).
Data Sources
Vaccination data were retrieved from each practice's electronic medical record. The following 2 periods with different but overlapping patient cohorts were compared: baseline (September 1, 2013 1, , to August 30, 2014 and intervention implementation phase (February 1, 2015 , to January 31, 2016 . The 6-month interval between these 2 time points was for "onboarding" intervention practices in implementation procedures. To ensure completeness, vaccination data were augmented with data from the Colorado Immunization Information System, to which all practices in the study actively reported. Data on all adolescents seen at least once during the study period were included in the analyses. Adolescents who were seen at multiple practices, who were deceased, or who were pregnant at the time of the visit (a contraindication for HPV vaccination) were excluded. Waivers of consent and Health Insurance Portability and Accountability Act of 1996 authorization were obtained to view adolescent vaccination records.
Medicaid insurance), proportion of medical professionals reporting "strongly" recommending the HPV vaccine for those aged 11 to 12 years, number of adolescent patients, 19 and medical specialty (family medicine and pediatrics). 20, 21 Because most practices did not collect patient race and ethnicity data, these were not used as a balance criterion. All possible combinations of eligible practices that would create 2 equal groups (8 intervention and 8 control) were generated using the IML procedure in SAS (version 9.4; SAS Institute Inc). The distribution of the balance criterion was then used to define an acceptable set of study groups that were reasonably balanced in terms of the selected variables.
22 From this, one set was randomly chosen and used to assign study arms. Health care professionals and the study team were not masked to the randomization category, but patients and analysts were.
Health Care Professional Communication Intervention
Intervention practices received a 5-component intervention that was designed based on the precaution-adoption-process model, 16 which distinguishes between various stages of the decision-making continuum (ie, unaware, aware but unengaged, undecided, etc) and was developed to provide tools and training that could be used before, during, or at the end of the clinical encounter. The intervention included the following:
(1) a fact sheet library that practices used to create practicespecific fact sheets about HPV infection and vaccination (eFigure1inSupplement 2), (2) a parent education website called "iVac" that created individually customized information about HPV vaccination (eFigure 2 in Supplement 2), (3) a series of disease images depicting diseases associated with HPV, (4) a decision aid for HPV vaccination (eFigure 3 in Supplement 2), and (5) communication training to improve health care professionals' vaccine recommendation practices. The communication training consisted of a self-guided, 30-minute webinar, plus 2 in-person, group training sessions that lasted 1 hour each. These sessions focused on opening the HPV vaccine conversation with a "presumptive approach," as defined by Opel et al, 23 followed by the use of motivational interviewing techniques for parents perceived as resistant to vaccination. Intervention practices worked with the study team over a series of 2 meetings lasting 1 hour each to develop and plan for implementation of the intervention within their practice, and each intervention practice chose a study champion to help facilitate the study activities. Medical professional surveys were administered quarterly to collect self-reported use of each tool kit component. Health care professionals in intervention practices received 25 Maintenance of Certification Part IV credits for participation. No other incentives were provided. A detailed description of intervention components, study planning meetings, and implementation procedures is provided in eMethods in Supplement 2.
Control Group
Practices in the control arm continued usual care with regard to communication about HPV vaccines. Health care professionals in the control arm did not receive any incentives for participation.
Sample Size Estimation
Sample size estimates were based on an assumed final sample size of 16 000 adolescents (8000 per arm), and vaccine use centered around 50% (the most conservative estimate). In a mixedeffects analysis with practice as a random effect and an estimated intraclass correlation coefficient of 2%, this sample size would provide 86% power (α = .05) to detect a 10-percentage point (PP) difference in differences in changes in HPV vaccination over time from the baseline to intervention implementation periods between control and intervention groups. Based on practice data, a period of 1 year was allocated to achieve this sample.
Primary and Secondary Study Outcome Measures
The primary outcome was the difference between control and intervention groups in changes over time in the proportion of eligible adolescents initiating (≥1 dose) the HPV vaccine series. Secondary outcomes were uptake of 2 other adolescent vaccines, the meningococcal conjugate vaccine (MenACWY) and the tetanus-diphtheria-acellular pertussis vaccine (Tdap). Completion (≥3 doses) of the HPV vaccine series was also assessed post hoc. The denominator for this analysis was the number of adolescents in the practice who had received the prior 2 doses of vaccine.
Covariates
Patient-level covariates included patient age (11-12 or 13-17 years), sex, race (white, black, or other), ethnicity (Hispanic or non-Hispanic), and insurance at the most recent visit (private, public, other, or none). Medical specialty (pediatrics or family medicine) and practice type (public or private) were hypothesized to be potential effect modifiers and were included in subgroup analyses to examine heterogeneity of treatment effects.
Statistical Analysis
We used an intent-to-treat analysis and generalized linear mixed models, 24, 25 as is recommended for cluster randomized trials. 26, 27 Clustering of patients within practices was accounted for with a random intercept for each practice. Models are presented as unadjusted and adjusted for covariates significantly associated with the outcome (P < .05) or variables representing factors known from prior research to be associated with HPV vaccination (medical specialty, practice type, age, sex, and insurance). 20, 21, 28, 29 The intraclass correlation coefficient was calculated using an intercept-only model. 30 Patients with unknown sex or with non-private or public insurance were excluded from this analysis. All P values are from 2-sided hypothesis tests. Statistical significance was defined at α = .05. Adjustments for multiplicity were not performed. All analyses used SAS software (version 9.4; SAS Institute Inc).
With the exception of the missed opportunities analyses, which were visit-level analyses, all analyses were patient level.
Heterogeneity of Treatment Effects
A series of moderator (effect modification) analyses assessed whether there were differential effects of the intervention by selected practice (medical specialty and practice type) and pa-tient (sex, race/ethnicity, and insurance) characteristics by examining the 3-way interaction term of time × study group × moderator and performing stratified analyses. Additional subgroup analyses were performed using (1) patients with a vaccination-eligible visit at age 11 to 12 years, (2) patients with a vaccination-eligible visit at age 13 to 17 years, (3) well-child care visits, and (4) sick visits (see eMethods in Supplement 2 for the definition of well or sick). Also assessed was the proportion of visits where adolescents had a missed opportunity for vaccination, defined as a clinic visit during the study period at which an adolescent was eligible for an HPV vaccine dose but did not receive it.
31,32
Health Care Professional Use and Perceptions
Descriptive statistics were generated from 7 quarterly health care professional surveys assessing the use of intervention components over time, given to 85 to 107 medical professionals (response rate, 85.5%-100%), depending on the staffing of the clinic at the time. A study describing the use of each tool kit component in detail is in preparation.
Results
Study Participants
All 16 practices in the study were assessed for vaccination outcomes ( Figure) . As summarized in Table 1 , patient and practice variables were mostly evenly distributed between groups except that a higher proportion of patients were reported as having public insurance in the intervention arm. Baseline vaccination rates among individuals aged 11 to 12 years, the variable used in the randomization process, were identical between arms. However, when the trial was completed, it became apparent that HPV vaccination rates among those aged 11 to 17 years differed slightly between arms (37.1% vs 31.6%) ( Table 2) .
Effect on HPV Vaccination Rates
Both the control and intervention groups significantly increased the proportion of eligible adolescents initiating the vaccine series over time (Table 2 and eFigure 4 in Supplement 2). However, in both unadjusted and adjusted models, these increases were significantly larger in the intervention group compared with control (1.8% increase control vs 11.3% increase intervention; 9.5-absolute PP difference, P < .001), with adjusted odds ratios (aORs) of 1.46 for initiation and 1.56 for completion ( Table 2 ). In contrast, series completion significantly decreased in the control practices, while remaining stable in the intervention practices, resulting in intervention practices having significantly higher odds of completing the series than control practices (Table 2 and eFigure 5 in Supplement 2). Heterogeneity of treatment effects analyses of HPV vaccine series initiation ( Table 3 ) and completion (eTable 1 in Supplement 2) by patient and practice characteristics showed that heterogeneity for HPV vaccination improvement was seen only for series initiation and occurred primarily at pediatric practices (medical specialty interaction term F 1,11 = 11.33, P = .006 for initiation and F 1,11 = 5.42, P = .04 for completion) and private practices (practice type interaction term F 1,13 = 33.63, P < .001 for initiation and F 1,13 =0. 76,P = .40 for completion). However, analyses were somewhat limited by the low numbers of adolescents eligible for the vaccine in family medicine practices overall.
Heterogeneity of treatment effects analyses assessed HPV vaccination initiation (Table 4 ) and completion (eTable 2 in Supplement 2) by adolescent age, sex, and insurance. Increases in series initiation among both age categories were higher in intervention practices than controls. There was no differential treatment effect by sex (sex interaction term F 1,13 = 0.01, P = .91 for initiation and F 1,13 = 1.58, P =.23for completion), but a differential treatment effect by patient insurance was seen for series initiation but not for completion (insurance interaction term F 1,13 =17 .8 5,P < .001 for initiation and F 1,13 = 2.47, P = .14 for completion). Series initiation increased substantially over time among patients with private insurance (aOR, 1.76; 95% CI, 1.55-1.99) but remained essentially unchanged among those with public insurance (aOR, 0.93; 95% CI, 0.76-1.14). Among the subset of practices with race (n = 6), and ethnicity (n = 2) data available, there were no differences in vaccination by the variables between study arms (eTable 3 and eTable 4 in Supplement 2).
Effect of MenACWY and Tdap Vaccination
Over time, there was a slight increase in MenACWY vaccination (0.4-PP increase to 62.8% for control and 2.1-PP increase to 55.6% for intervention) and a slight decrease in Tdap vaccination (3.4-PP decrease to 60.1% for control and 7.0-PP decrease to 50.1% for intervention). Neither comparison between study arms was significant (eTable 5 in Supplement 2). Clinics were randomized by (1) count of patients who were aged 9 to 17 years, (2) percentage of patients who were eligible for the Vaccines for Children program, (3) percentage of health care professionals who strongly recommend human papillomavirus vaccine to girls aged 11 to 12 years, and (4) human papillomavirus vaccine initiation rates among patients aged 11 to 12 years. CONSORT indicates Consolidated Standards of Reporting Trials.
Effect on Missed Opportunities for Vaccination
Overall, there was a significant reduction in missed opportunities for vaccination in intervention practices compared with controls (eFigure 6 in Supplement 2). This difference was significant for well-child care checkups (aOR, 0.61; 95% CI, 0.54-0.69) but not for sick visits (aOR, 0.87; 95% CI, 0.68-1.12). 
Discussion
Implementation of a health care professional communication intervention to improve adolescent HPV vaccination resulted in a 9.5-PP increase in HPV vaccine series initiation compared with control practices, which was both clinically and statistically significant. The use of the intervention materials, particularly the communication techniques and fact sheets, was sustained over the 12-month intervention implementation period, and medical professionals intended to continue to use these components in the future. The intervention also mitigated decreases over time in HPV vaccine series completion. To our knowledge, there are 2 other intervention studies that have focused on health care professional communication for improving HPV vaccination. Brewer and colleagues 33 tested the effect of "announcements" (similar to the presumptive communication style) vs "conversations" (similar to the participatory communication style) on HPV vaccination levels in 29 practices. At the 6-month assessment, announcement practices had a 5.4-PP increase in HPV vaccine series initiation and no changes in receipt of Tdap, MenACWY, or HPV vaccine series completion compared with controls. In a smaller study, Perkins et al 34 implemented a multicomponent intervention that included practice coaching every 4 to 6 weeks, HPV education for medical professionals (including "basic motivational interviewing principles," assessment, and feedback on practices' HPV vaccination rates compared with others in their region), and Maintenance of Certification part IV incentives. The HPV vaccination rates were higher in the intervention practice during the active study phase than controls but were sustained only for male participants when assessed 6 months later. Placing our results in this context, it seems that, while a presumptive/announcement approach to the initial HPV vaccine conversation can increase HPV vaccine initiation, there is added benefit to using additional components in our intervention, namely, the motivational interviewing training and customized HPV fact sheets. Inclusion of these items could explain why our intervention had a greater effect than that of the study by Brewer and colleagues, 33 positively affected series completion, and seemed to have a sustained effect over a longer period compared with the study by Perkins et al.
34
Our intervention appeared less effective in public compared with private practices. This result is opposite of what might be expected given that national data consistently demonstrate increased adolescent HPV vaccine uptake among populations typically served by public clinics. 28, [35] [36] [37] [38] When examined at the practice level, 2 of the public practices in the intervention arm increased HPV vaccine series initiation levels (by 7.8% and 13.0% over time), whereas the third one decreased by 3.5%. One explanation for this could be that the third practice, which was substantially larger than the other 2, had a large number of trainees, and not all health care professionals were able to fully participate in the intervention training sessions and study meetings, effectively diluting any effect the intervention may have had in this practice. Improvements in HPV vaccination among intervention practices occurred primarily at well-child care visits. While there was some decrease in missed opportunities for vaccination at sick visits in intervention practices, this decrease was small, and most vaccines were still provided during routine wellness examinations. Anecdotal reports from health care professionals in our study indicate that lack of time and prioritization of other health issues make vaccination at sick visits difficult, a finding that is supported by several other studies. 
Limitations
This trial had some limitations. First, the most important limitation of our study was that we could not directly examine at an individual patient level the effect of specific intervention components on HPV vaccine uptake. Health care professionals reported quarterly on which intervention components they used during the previous month, rather than after each patient visit. The intervention was developed to be adaptable based on each practice's and medical professional's needs, resulting in variability between and within practices of which intervention components were used and under what circumstances. Based on health care professionals' reports, it appears that the communication training and fact sheets were the most used and useful intervention components. Further research is needed to understand if the other components are needed. Second, an additional limitation is that having an immunization champion and the 2-hour planning meetings with practices, while not part of the intervention per se, could have also had an effect on vaccination rates. This effect was not specifically assessed. Third, we could only assess the vaccination status of the patients who had a clinic visit during the study period. Our intervention was not designed to affect patients who are not seen for care. Fourth, our intervention focused on a single geographic area and may not be generalizable. Fifth, although baseline assessments of HPV vaccination status among those aged 11 to 12 years was identical between arms, baseline vaccination status among those aged 11 to 17 years was slightly lower among intervention practices than control practices, which could have influenced the degree to which the intervention increased vaccination rates. Sixth, the overall in-fluence of the intervention was modest, and all practices' vaccination levels remained well below the national goal of 80% coverage.
Conclusions
In this cluster randomized clinical trial of a health care professional HPV vaccine communication intervention, there were substantial and sustained increases in HPV vaccine series initiation in intervention practices compared with controls over time. Medical professionals used some tool kit components more than others and planned to continue to use them in the future. Future research will need to examine if similar effects on vaccination rates can be achieved through more generalizable dissemination methods, such as via the internet or through the public health department network. 
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eMethods. Supplemental Methods
A full copy of the trial protocol is available from the authors upon request.
Analytic Cohorts:
Data were analyzed across three age cohorts: (1) 11-12 year olds, (2) 13-17 year olds, (3) 11-17 year olds. For inclusion in any cohort a patient was required to have had at least one clinic visit where they meet the cohort age criteria. Only visits where the child's age was within the cohort age range were included in each cohort analyses. Age cohorts of 11-12 year olds and 13-17 year olds are not mutually exclusive. Demographics for each patient were retained from their most recent visit.
Variable Definitions:
Pregnancy related visits were identified by ICD-9-CM codes V22, V23, 632-638, 650-659, or their ICD-10-CM equivalent (Centers for Medicare & Medicaid Services General Equivalence Mappings http://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-equivalence-mapping.html, accessed 03/15/2016).
Well visits were defined by the presence of either an ICD-9-CM code (V20. 2, V70.0, V70.3, V70.5, V70.6, V70.8, V70.9) or CPT code (99383, 99384, 99385, 99393, 99394, 99395) for a well exam. For practices where codes were not provided, well visits were identified by visit type descriptions. For practices converting to ICD-10-CM coding during the study equivalent codes were determined from the Centers for Medicare & Medicaid Services General Equivalence Mappings (http://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-equivalence-mapping.html, accessed 03/15/2016). All other visits were considered sick visits. As patients could be eligible for HPV vaccine at both a well encounter and a sick encounter, these groupings are not mutually exclusive.
Detailed Description of Intervention Components HPV Fact Sheet Library:
The Fact Sheet Library consisted of text, images, and graphics related to HPV infection and vaccination and a single page, double-sided template for creating the sheets. Practice providers and staff voted on the elements from the Library they wanted to incorporate in their Fact Sheet. The study team then created a draft of the Fact Sheet using the template. Through an iterative feedback process with the practice's providers a final version of the Fact Sheet was created. These sheets were then printed in color and provided to the practice for use. Two examples of Fact Sheets created by study practices are provided in eFigure 1.
Tailored Website for Parents:
The tailored website for parents, called "iVac HPV" was HPV specific and developed based on a prior version of the website that included information about all adolescent vaccines, and is depicted in eFigure 2. To use the website, parents first answered a short baseline survey embedded in the website that collected information about their attitudes, beliefs and experiences related to HPV infection, disease and vaccination. Upon completion, parents were automatically taken to educational information about HPV vaccination and infection that was customized for them based on the information they input into the baseline survey. Customization occurred on three levels: 1) the text throughout the multi-paged website reflected each parent's main concerns and questions about HPV; 2) pictures placed throughout the website matched the parent's self-reported race and gender; and 3) parents were asked to provide the first name of their child and this name was used throughout the text to personalize the information. Screen shots of the website are shown in Appendix Figure 2 . Practices who chose to use the website did so in a variety of ways including having iPads or kiosks placed in the clinic's waiting rooms, having the website available on computers in the exam rooms, or posting the website address on their clinic's website and encouraging parents to look at it prior to their appointment.
Disease Images: The study team created binders that provided gender-specific photo representations of genital warts, penile cancer, vaginal cancer, vulvar cancer, cervical cancer, and oropharyngeal cancer. Practices that chose to use this intervention component kept the binder at a central location in the clinic and brought it into the patient rooms when they felt it was appropriate.
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HPV Vaccine Decision Aid:
The HPV Vaccine Decision Aid was developed to provide parents with concrete information to inform decision-making about HPV vaccination if a conversation with the provider was not enough to help them make a decision. The Decision Aid was available as a 2-sided piece of paper that was provided to practices to use as they wished. It included information about the risks of vaccinating versus not vaccinating, and action steps for parents to take based on their current thoughts about the vaccine. The Decision Aid is provided in eFigure 3. 
Implementation of Intervention Components
During the study planning meetings, intervention practices made decisions about which components of the intervention to use, and how to incorporate these into their clinic's workflow. There was variability among the practices in these decisions, which are summarized as follows.
Fact Sheet: All intervention practices chose to use the fact sheet. Some practices provided this upon check in for all patients, some at check in for patients that the MA screened as being potentially HPV vaccine hesitant, and some provided the information sheet during the clinic visit, when parents had questions about the vaccines. One practice had the fact sheets laminated and posted in each exam room. One practice made the FS available on their website. One practice included the FS in the 10-11 year old annual visit packet.
iVac website: All practices elected to use the iVac website but there was high variability in its implementation. One practice chose to have a link to the website available on their office's home page where parents routinely went to fill out pre-visit paperwork and questionnaires, Six practices had the website available on portable iPads or iPads in kiosks that were available to patients by the MA during a clinic visit if they had questions, One practice had a link to the website on each exam room computer that the provider could pull up for parents during a clinic visit if needed.
Decision Aid: All practices elected to use the Decision Aid. One practice's MAs provided this to parents if they believed the parent to be HPV vaccine hesitant when checking in the patient (prior to the provider seeing the patient). The completed worksheet was hoped to facilitate the HPV vaccine conversation between parent and provider. Another practice stapled the Decision Aid to a Vaccine refusal form, which they had the parent sign when refusing the vaccine. After gaining the signature, the MA would tear off the DA and provide that to the parent to take home. The remaining practices had the Decision Aid available in the exam rooms to use during or at the end of the clinical visit, as needed.
Disease images: Only 6 practices elected to use the disease images library. One practice kept notebooks with the images in a centralized location that providers could use as needed. The others kept a packet of the images in each exam room, in a secure location, to be used during visits as needed. Disease images were laminated hard copies at all practices, except one practice choose to also have the images on the exam room computer desktops.
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Communication training: Communication training was offered to all "providers" (MD, PA, NP) that could prescribe the vaccine in the intervention offices; it was required by medical providers (MD) wishing to receive MOC Part IV credits. If a provider was not able to attend an in person training session, a video link to a previous training session at another practice was provided instead. However, providers were strongly encouraged to attend the sessions in person. Attestation of having viewed the introduction and background video and attendance at both in-person sessions (or viewing a make-up session) was required for receipt of MOC Part IV credit. Attendance at all 3 sessions was required for receipt of MOC Part IV credit.
Study Meetings
In the 6 months on-boarding period that occurred prior to the launch of the intervention, 2 hour long study planning and training meetings occurred at each of the intervention practices. The content of these meetings was as follows:
Meeting 1: The research team re-oriented practices to the study, administered a baseline survey regarding current communication techniques, asked participants to choose the intervention components they wished to use, and asked participants to "vote" on the elements from the Fact Sheet Library (provided in paper format) that they wanted to include in their practice's customized HPV Fact Sheet.
Meeting 2:
The research team presented draft versions of each Practices HPV Fact Sheet based on the results from the previous assessment, conducted process mapping with the practice to decide when and how each selected intervention component would be implemented at the practice.
Results
Increases in HPV vaccination initiation and completion, by practice, are depicted in eFigures 4 and 5, respectively. Thirteen of sixteen practices increased HPV vaccine series initiation over time. Series completion was lower over time in most practices.
Data on HPV vaccine series completion by clinic and patient factors are depicted in eTables 1 and 2 respectively. As with series initiation, improvements in intervention practices in series completion were more prominent in well child exams at private pediatric clinics. Data on HPV vaccine series initiation by race and ethnicity is depicted in eTable 3.
eFigure 6 depicts changes in missed opportunities for vaccination from baseline, comparing intervention and control practices. Reductions in missed opportunities were significantly greater among intervention than control practices for well visits, and slightly greater for sick visits.
